Table II.
Genotype and allele frequencies of CYP3A5*3, CYP3A4*18 and CYP2B6*6
| SNP | Frequency (%) | P (χ2) | ||
|---|---|---|---|---|
|
| ||||
| IM good response (n=51), n (%) | IM resistant (n=102), n (%) | |||
| CYP3A5*3 (rs776746) | ||||
| Genotype | ||||
| Homozygous wild type (AA) | 0 | 1 (0.98) | 0.478δ | |
| Heterozygous (AG) | 0 | 0 | ||
| Homozygous mutant (GG) | 51 (100) | 101 (99.02) | ||
| Allele | ||||
| A | 0 | 2 (0.98) | 0.316δ | |
| G | 102 (100) | 202 (99.02) | ||
| CYP3A4*18 (rs28371759) | ||||
| Genotype | ||||
| Homozygous wild type (TT) | 48 (94.12) | 102 (100) | 0.013δ | |
| Heterozygous (TC) | 3 (5.88) | 0 | ||
| Homozygous mutant (CC) | 0 | 0 | ||
| Allele | ||||
| T | 99 (97.1) | 204 (100) | 0.036δ | |
| C | 3 (2.9) | 0 | ||
| CYP2B6*6 (rs3745274) | ||||
| Genotype | ||||
| Homozygous wild type (GG) | 24 (47.06) | 50 (49.02) | 0.737 (0.61) | |
| Heterozygous (GT) | 17 (33.33) | 37 (36.27) | ||
| Homozygous mutant (TT) | 10 (19.61) | 15 (14.71) | ||
| Allele | ||||
| G | 65 (63.7) | 137 (67.1) | 0.609 (0.357) | |
| T | 37 (36.3) | 67 (32.9) | ||
δTest statistic not reported for Fisher’s exact test. IM, imatinib mesylate